Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science

References

• Stigler GJ. The theory of Price. Macmillan; 1952.
   Google Scholar
• Weber TA. Price theory in economics. Oxford Handb Pricing Manag. 2012:281–339.
   Google Scholar
• Morgan S McMahon M Greyson D. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia. Health Policy (New York). 2008;87:133–145.
   Web of Science ®Google Scholar
• Rand RB. Pharmaceutical advertising to doctors. J Bus Univ Chicago. 1941;14:150–168.
   Google Scholar
• Branch FT. A comparison of direct-mail and magazine cost in pharmaceutical advertising. J Bus Univ Chicago. 1945;18:78–95.
   Google Scholar
• Reekie WD. Some problems associated with the Marketing of Ethical Pharmaceutical Products. J Ind Econ. 1970;19:33–49.
   Google Scholar
• Greene JA Podolsky SH. Reform, regulation, and pharmaceuticals--the Kefauver-Harris amendments at 50. N Engl J Med. 2012;367:1481–1483.
   PubMed Web of Science ®Google Scholar
• Steele H. Patent restrictions and Price competition in the ethical drugs industry. J Ind Econ Wiley. 1964;12:198–223.
   Web of Science ®Google Scholar
• Means GC. The administered-Price thesis reconfirmed. Am Econ Rev. 1972;62:292–306.
   Web of Science ®Google Scholar
• Means GC. Industrial Prices and Their Relative Inflexibility, U.S., Congress, Senate, 74th Cong., 1st sess., 1935, document 13.
   Google Scholar
• Cocks DL Virts JR. Pricing behavior of the ethical pharmaceutical industry. J Bus. 1974;47:349–362.
   Web of Science ®Google Scholar
• Comanor WS. The political economy of the pharmaceutical industry. J Econ Lit. 1986;24:1178–1217.
   PubMed Web of Science ®Google Scholar
• Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J. 2002;43:453–461.
   PubMed Web of Science ®Google Scholar
• Frank RG Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ <html_ent glyph=“@amp;” ascii=“&amp;”/> Manag Strateg. 1997;6:75–90. Cambridge, MA.
   Web of Science ®Google Scholar
• Hudson J. Pricing dynamics in the pharmaceutical industry. Appl Econ. 1992;24:103–112.
   Web of Science ®Google Scholar
• Backhaus J. Competition, innovation and regulation in the pharmaceutical industry. Manag Decis Econ. 1983;4:107–121.
   Web of Science ®Google Scholar
• Kaiser U Mendez SJ Rønde T Ullrich H. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. J Health Econ. 2014;36:174–187.
   PubMed Web of Science ®Google Scholar
• Drummond M Jönsson B Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40:199–215.
   PubMed Web of Science ®Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Canadian guidelines for economic evaluation of pharmaceuticals. 2nd ed. Pharmacoeconomics. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
   Google Scholar
• Jayadev A Stiglitz J. Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Aff (Millwood). 2009;28:w165–w168.
   PubMed Web of Science ®Google Scholar
• Arksey H O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
   Google Scholar
• Colquhoun HL Levac D O’Brien KK Straus S Tricco AC Perrier L, et al. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol. 2014;67:1291–1294.
   PubMed Web of Science ®Google Scholar
• Fiocruz. ARCA. Repositório Institucional da Fiocruz. [internet] Available from www.arca.fiocruz.br.
   Google Scholar
• Friedman D. Price theory: an intermediate text: SUNY-Oswego, Department of Economics; 1990.
   Google Scholar
• Berry S Levinsohn J Pakes A. Automobile Prices in Market Equilibrium. Econometrica. 1995;63:841–890.
   Web of Science ®Google Scholar
• Kina SH, Wosinska M. Pharmaceutical Pricing. Handb Pricing Res Mark. Edward Elgar Publishing; p. 488–511.
   Google Scholar
• World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. WHO Guidel Ctry Pharm Pricing Policies. 2015;134.
   Google Scholar
• Reiss J. Two approaches to reasoning from evidence or what econometrics can learn from biomedical research. J Econ Methodol. 2015;22:373–390.
   Web of Science ®Google Scholar
• Hoover KD. The methodology of econometrics. SSRN Electron J. 2005.
   Google Scholar
• Braun V Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
   Google Scholar
• Vaismoradi M Turunen H Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15:398–405.
   PubMed Web of Science ®Google Scholar
• Danzon PM Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3:183–205.
   PubMedGoogle Scholar
• Rojas M. Price discrimination by pharmaceutical companies across central American countries. Int J Pharm Healthc Mark. 2009;3:118–136.
   Google Scholar
• Moon S Jambert E Childs M von Schoen-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Glob Health. 2011;7:39.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G Truter I Lubbe MS Cottrell W Spirovski B Edwards J. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. J Eval Clin Pract. 2012;18:343–351.
   PubMed Web of Science ®Google Scholar
• Baseilhac E. Toward a conditional price for medicine? Ann Pharm Fr. 2013;71:330–337.
   PubMedGoogle Scholar
• Henschke C Sundmacher L Busse R. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation. Health Policy. 2013;109:263–269.
   PubMed Web of Science ®Google Scholar
• Megerlin F. Médicaments innovants et prix conditionnels : le contrat de performance, à l’opposé du partage de risques. Ann Pharm Françaises. 2013;71:291–301.
   PubMedGoogle Scholar
• Fuller RL Goldfield N. Paying for On-Patent Pharmaceuticals: limit prices and the emerging role of a pay for outcomes approach. J Ambul Care Manage. 2016;39:143–149.
   PubMedGoogle Scholar
• Stargardt T Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy. 2006;5:235–247.
   PubMedGoogle Scholar
• Miraldo M. Reference pricing and firms’ pricing strategies. J Health Econ. 2009;28:176–197.
   PubMed Web of Science ®Google Scholar
• Dukes MNG, Ruskamp F, Joncheere C, Rietveld A. Drugs and Money: Prices, Affordability and Cost Containment. Organization WH, editor. IOS Press; 2003.
   Google Scholar
• Sarmento AZ. Alternative drug Price policies in the Americas. WHO; 1995.
   Google Scholar
• World Health Organization (WHO). Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines, Meeting Report, 19–21 February 2001, Chulalongkorn University, Bangkok, Thailand - Health Economics and Drugs Series No. 011. 2002.
   Google Scholar
• Brudon P, Fresle D, Hogerzeil HV, Quick JD, Sodogandji T, Strategy RD. Globalization and Access to Drugs. Perspectives on the WTO/TRIPS Agreement - Health Economics and Drugs Series, No. 007 (Revised). 1998.
   Google Scholar
• Boulet P, Hanvoravongchai P, Velásquez G. Globalization, Patents and Drugs (Second Edition). An Annotated Bibliography - Health Economics and Drugs Series No. 010. 2001;
   Google Scholar
• World Health Organization (WHO). Determining the Patent Status of Essential Medicines in Developing Countries - Health Economics and Drugs Series No. 017. 2004. p. 24.
   Google Scholar
• Correa CM. Implementation of the Wto general council decision on paragraph 6 of the Doha declaration on the Trips agreement and public health. Public Health. 2004;49.
   Google Scholar
• World Health Organization (WHO). Remuneration Guidelines for Non-voluntary Use of a Patent on Medical Technologies - Health Economic and Drugs Series No. 018. 2005. p. 110.
   Google Scholar
• World Health Organization. Measuring medicine prices, availability, affordability and price components. WHO Tech Rep Ser. 2007;20:763–765.
   Google Scholar
• Babar Z-U-D. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015.
   Google Scholar
• Lima L De, Pastrana T, Radbruch L. Cross-Sectional Pilot Study to Monitor the Availability , Dispensed Prices, and Affordability of Opioids Around the Globe. J Pain Symptom Manage. Elsevier Inc; 2014;
   Google Scholar
• World Health Organization (WHO). “Better Medicines for Children Project ” Overview of Methods for Medicines Availability and Pricing Surveys. 2009.
   Google Scholar
• Paulden M Stafinski T Menon D McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33:255–269.
   PubMed Web of Science ®Google Scholar
• Emmerick ICM Oliveira MA Luiza VL Azeredo TB Bigdeli M. Access to medicines in Latin America and the Caribbean (LAC): a scoping study. BMJ Open. 2013;3:e002224.
   PubMed Web of Science ®Google Scholar
• Bashaar MA Hassali FS ALrasheedy AA Thawani V. Efficacy of international approaches to medicine price regulation and control: A scoping review. J Appl Pharm Sci. 2017;7:227–241.
   Google Scholar
• Alexander GC Ballreich J Socal MP Karmarkar T Trujillo A Greene J, et al. Reducing branded prescription drug prices: A review of policy options. Pharmacotherapy. 2017;37:1469–1478.
   PubMed Web of Science ®Google Scholar
• Gregson N Sparrowhawk K Mauskopf J Paul J. Pricing medicines: theory and practice, challenges and opportunities. Nat Rev Drug Discov. 2005;4:121–130.
   PubMed Web of Science ®Google Scholar
• Adriaen M De Witte K Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. J Generic Med. 2008;5:175–187.
   Google Scholar
• Lu ZJ Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat. 1998;80:108–118.
   Web of Science ®Google Scholar
• Vogler S Zimmermann N Habl C Piessnegger J Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev. 2012;5:38–46.
   PubMedGoogle Scholar
• Danzon PM Mulcahy AW Towse AK. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ. 2015;24:238–252.
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Holtorf A-P, Otávio Corrêa J, Gialama F, Wijaya K. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage. Appl Health Econ Health Policy. 2018;
   Google Scholar
• Daems R Maes E Glaetzer C. Equity in pharmaceutical pricing and reimbursement: crossing the income divide in Asia Pacific. Value Heal Reg Issues. 2013;2:160–166.
   PubMedGoogle Scholar
• Vandoros S Kanavos P. Parallel trade and pharmaceutical prices: A game-theoretic approach and empirical evidence from the European Union. World Econ. 2014;37:856–880.
   Web of Science ®Google Scholar
• Brekke KR Holmås TH Straume OR. Price regulation and parallel imports of pharmaceuticals. J Public Econ. 2015;129:92–105.
   Web of Science ®Google Scholar
• Vernon JA. The relationship between price regulation and pharmaceutical profit margins. Appl Econ Lett. 2003;10:467–470.
   Web of Science ®Google Scholar
• Maïga D Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy. 2010;97:130–135.
   PubMed Web of Science ®Google Scholar
• von der Schulenburg F Vandoros S Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Econ Rev. 2011;1:18. Springer Open Ltd.
   PubMedGoogle Scholar
• Andersson F. Norway’s pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn? Health Policy (New York). 1992;21:17–34.
   Web of Science ®Google Scholar
• Huttin C. The Chinese medicines market: moving towards a market system? Health Policy. 1994;29:247–259.
   PubMed Web of Science ®Google Scholar
• Ali GKM Yahia Y. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority. East Mediterr Health J. 2012;18:811–820.
   PubMedGoogle Scholar
• Schut FT Van Bergeijk PAG. International price discrimination: the pharmaceutical industry. World Dev. 1986;14:1141–1150.
   Web of Science ®Google Scholar
• Danzon PM Chao LW. Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19:159–195.
   PubMed Web of Science ®Google Scholar
• Shajarizadeh A Hollis A. Price-cap regulation, uncertainty and the Price evolution of new pharmaceuticals. Health Econ. 2015;24:966–977.
   PubMed Web of Science ®Google Scholar
• Liu Y-M Yang Y-HK Hsieh C-R. Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. J Health Econ. 2012;31:471–483.
   PubMed Web of Science ®Google Scholar
• Ghislandi S Armeni P Jommi C. The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ. 2013;14:959–969.
   PubMed Web of Science ®Google Scholar
• Kaier K. The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials. Health Econ Policy Law. 2013;8:7–20.
   PubMed Web of Science ®Google Scholar
• Busse R Schreyögg J Henke K-D. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manag. 2005;20:329–349.
   PubMed Web of Science ®Google Scholar
• Morrison A Polisena J Husereau D Moulton K Clark M Fiander M, et al. The effect of ENGLISH-language restriction on systematic review-based META-analyses: A systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28:138–144.
   PubMed Web of Science ®Google Scholar
• Tricco AC Lillie E Zarin W O’Brien K Colquhoun H Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16:15.
   PubMed Web of Science ®Google Scholar
• Tricco AC Lillie E Zarin W O’Brien KK Colquhoun H Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467
   PubMed Web of Science ®Google Scholar
• Kesselheim Aaron S. Avorn Jerry Sarpatwari Ameet. The High Cost of Prescription Drugs in the United States: origins and prospects for reform. JAMA. 316:858–71.
   PubMed Web of Science ®Google Scholar
• Nishtar S Niinistö S Sirisena M Vázquez T Skvortsova V Rubinstein A, et al. Time to deliver: report of the WHO independent high-level commission on NCDs. Lancet. 2018;392:245–252.
   PubMed Web of Science ®Google Scholar
• Brownson RC Roux AVD Swartz K. Commentary: generating rigorous evidence for public health: the need for new thinking to improve research and practice. Annu Rev Public Health. 2014;35:1–7.
   PubMed Web of Science ®Google Scholar
• Angrist J, Pischke J-S. The credibility revolution in empirical economics: how better research design is taking the con out of econometrics. Cambridge, MA; 2010.
   Google Scholar